SCHEMBL7054463

SCHEMBL7054463

CCC(C(=O)O[SiH3])(c1ccccc1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.58
CHRM1 P11229 2/20 0.58
CHRM3 P20309 2/20 0.58
KCNN4 O15554 1/20 0.46
OPRM1 P35372 5/20 0.45
DRD3 P35462 3/20 0.45
DRD2 P14416 1/20 0.45
SCN1A P35498 3/20 0.44
SCN2A Q99250 3/20 0.44
SCN3A Q9NY46 3/20 0.44
CYP2C19 P33261 3/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
MTOR P42345 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27382896 0.85 KCNN4 (0.60) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL7057728 0.83 SCN1A (0.48) CHRM2CHRM1CHRM3OPRM1DRD3
SCHEMBL7056880 0.83 SCN1A (0.48) CHRM2CHRM1CHRM3OPRM1DRD3
Hydrochloric Acid SCHEMBL27398566 0.83 KCNN4 (0.58) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL28970082 0.83 CHRM2 (0.65) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL8675044 0.83 CHRM2 (0.56) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL8675338 0.83 CHRM2 (0.56) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL27262733 0.81 CHRM2 (0.55) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL27472652 0.81 CHRM2 (0.55) CHRM2CHRM1CHRM3KCNN4OPRM1
SCHEMBL705142 0.81 KCNN4 (0.46) CHRM2CHRM1CHRM3KCNN4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1006118-B1 Method for synthesizing organosilicon compounds that contain a group bonded to silicon across the SI-C bond DOW CORNING ASIA LTD (JP) 2003-05-07 EP disclosed
US-6441023-B1 FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION AMERICAN HOME PRODUCTS CORPORATION 2002-08-27 US disclosed
US-20020032186-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors AMERICAN CYANAMID COMPANY (US) 2002-03-14 US disclosed
EP-1085022-A1 A method of manufacturing an acyloxysilane compound having functional groups bonded to silicon atoms via Si-C- bonds Dow Corning Asia, Ltd. (JP) 2001-03-21 EP disclosed
US-6175031-B1 PLATINUM-CATALYZED HYDROSILYLATION BETWEEN SIH-SUBSTITUTED SILICON COMPOUNDS AND UNSATURATED GROUP-FUNCTIONAL ORGANIC OR ORGANOSILICON COMPOUNDS IN PRESENCE OF A (ACYLOXY)-FUNCTIONAL HYDROGENSILANE COMPOUND OR ACID AND HYDRO(ALKOXY)SILANE DOW CORNING ASIA, LTD. (JP) 2001-01-16 US disclosed
US-6111126-A Method for synthesizing organosilicon compounds that contain a functional group bonded to silicon across the Si-C bond DOW CORNING ASIA, LTD. (JP) 2000-08-29 US disclosed
EP-1006118-A2 Method for synthesizing organosilicon compounds that contain a group bonded to silicon across the SI-C bond Dow Corning Asia, Ltd. (JP) 2000-06-07 EP disclosed
US-6060620-A Method for manufacturing an acyloxysilane compound having functional groups bonded to silicon atoms via SI--C bonds DOW CORNING ASIA, LTD. (JP) 2000-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032186-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors MMP12, ADAM33, MMP2 CHRM2 4575/4885CHRM1 4561/4885CHRM3 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.